Mapping the Angiotensin II-TGFB-Integrin signaling triad to reveal therapeutic targets in aortic aneurysm

绘制血管紧张素 II-TGFB-整合素信号三联体图谱以揭示主动脉瘤的治疗靶点

• 批准号: 9108213
• 负责人: Sarah J Parker
• 金额: $ 17.1万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-15 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9108213
• 关键词: Accounting; Adhesions; Affect; Aneurysm; Angiotensin II; Aorta; Aortic Aneurysm; Apoptosis; Apoptotic; Area; Attenuated; Award; Binding; Biological; Biology; Blood Vessels; California; Cardiovascular Physiology; Cardiovascular system; Cell physiology; Cereals; Cessation of life; Characteristics; Clinical; Clinical Research; Collaborations; Communication; Complex; Connective Tissue Diseases; Cytoskeletal Modeling; Cytoskeleton; Data; Data Set; Development; Disease; Dissection; Doctor of Philosophy; Elastin; Elements; Environment; Event; Excision; Extracellular Matrix; FBN1; Fellowship; Film; Fostering; Functional disorder; Generations; Genes; Genetic; Genetic study; Goals; Growth; Hereditary Disease; In Situ; In Vitro; Informatics; Institution; Integrin beta3; Integrins; Intervention; Knock-in Mouse; Knock-out; Laboratories; Lead; Leadership; Ligands; Link; Losartan; MADH2 gene; MAPK3 gene; Malignant Neoplasms; Maps; Marfan Syndrome; Mass Spectrum Analysis; Matrix Metalloproteinases; Mechanics; Medial; Mediating; Mediator of activation protein; Medical Genetics; Medical center; Mentors; Mentorship; Molecular; Mus; Mutation; Operative Surgical Procedures; Organ; Pathogenesis; Pathology; Pathway interactions; Patient Care; Pharmaceutical Preparations; Pharmacological Treatment; Phase; Phenotype; Physiological; Physiology; Postdoctoral Fellow; Principal Investigator; Property; Proteomics; Receptor Cross-Talk; Receptor Signaling; Receptor, Angiotensin, Type 1; Research; Research Institute; Research Personnel; Rupture; Signal Transduction; Smooth Muscle Myocytes; Stimulus; TGFB1 gene; Techniques; Technology; Testing; Thoracic Aortic Aneurysm; Tissues; Training; Transforming Growth Factors; Translating; Triad Acrylic Resin; United States; Universities; Validation; Vascular Smooth Muscle; Wisconsin; arrestin 2; base; beta-arrestin; career; cell type; design; extracellular; high risk; in vitro Model; in vivo; insight; medical schools; mouse model; muscle engineering; new therapeutic target; novel; novel therapeutics; overexpression; prevent; programs; research clinical testing; research study; skills; success; targeted biomarker; therapeutic target; transmission process

 DESCRIPTION (provided by applicant): PROJECT SUMMARY Aortic aneurysm is a prevalent condition defined by excessive aortic growth and medial wall remodeling that can result in lethal dissection and rupture. Few effective pharmacological treatments exist for aneurysm, due in large part to an incomplete understanding of the mechanisms that underlie the disease. The goal of this proposal is to derive a more comprehensive understanding of the molecular events that belie thoracic aortic aneurysm progression, and in so doing identify and validate potential targets for novel pharmacological therapy. Preliminary in vitro and in vivo data indicate that interactions between angiotensin II, integrin, and transforming growth factor β (TGFβ) signaling are key molecular elements of aneurysm pathogenesis. The principal investigator, Dr. Sarah Parker, uses a genetic knock-in mouse model of Marfan syndrome (MFS) to study the context-dependent molecular mechanisms leading to dysregulated TGFβ signaling in thoracic aortic aneurysm. In the mentored phase of this proposal, Dr. Parker will use in vitro techniques to assess how of Integrin β3 (ITGβ3) overexpression, as occurs in MFS, impacts aspects of vascular smooth muscle cell physiology known to be altered in aortic aneurysm, and use novel mass spectrometry technologies (data independent acquisition MS) to identify pathogenic signaling components downstream of ITGβ3 that drive altered VSMC physiology (Aim 1). In the transition to the independent phase, Dr. Parker will identify how another signaling network, β-Arrestin 2 (βARR2) biased signaling by the Angiotensin II Type 1 Receptor (AT1R), contributes to dysregulated TGFβ signaling and altered mechanical properties of VSMCs that occur during aneurysm in MFS (Aim 2). Finally, Dr. Parker will integrate the findings in Aims 1 and 2 to test a unifying hypothesis that altered matrix sensing by ITGβ3 contributes to βARR2 biased signaling by AT1R both in vitro as well as in vivo in MFS mice, and further determine whether pharmacological manipulation of ITGβ3 and/or βARR2-biased signaling can attenuate aneurysm progression in MFS (Aim 3). Dr. Parker received her Ph.D. in Physiology from the Medical College of Wisconsin (MCW). She has subsequently completed the first three and a half years of her Post Doctoral fellowship at Johns Hopkins University under the collaborative mentorship of Dr. Harry (Hal) Dietz, a renowned clinician and expert in the medical genetics of connective tissue disorders and aortic aneurysm, and Dr. Jennifer Van Eyk, a premier expert in clinical cardiovascular proteomics. Building upon her established expertise in cardiovascular physiology and mass spectrometry-based proteomic techniques, this K99/R00 award will allow Dr. Parker to (1) develop informatics and computational skills for the analysis and interpretation of complex molecular data sets, (2) in collaboration with Dr. Megan McCain at the University of Southern California, develop an in vitro model to independently modify matrix components, smooth muscle cell types, and soluble extracellular factors in order to study contractile physiology in smooth muscle cells, (3) continue to build expertise in the vascular biology of the aorta and (4) strengthen her communication, mentoring, management, and leadership skills to prepare for success as an independent biomedical researcher. Dr. Parker will complete the mentored phase of this award at Cedars-Sinai Medical Center (CSMC), where her primary mentor, Dr. Van Eyk, has recently moved her laboratory to become the director of the Advanced Clinical Biosystems Research Institute. Dr. Parker has enlisted an impressive team of mentors and advisors both local to Cedars Sinai (Dr. Jennifer Van Eyk, Dr. Moshe Arditi, Dr. Ben Berman, Dr. Ken Bernstein) and at external institutions (Dr. Hal Dietz, Dr. John Yates, and Dr. Megan McCain) to facilitate her scientific and personal development. The clinical research environments fostered by the institutions where Dr. Parker has been trained (Johns Hopkins, MCW) and will continue her training (CSMC) provide ideal settings to facilitate her long-term career goal to elucidate context-dependent, pathological signaling events in situ and connect them with the altered cellular, tissue, and organ physiology characteristic of disease pathogenesis. Dr. Parker will first focus her approach on the specific etiological mechanisms that drive ascending aortic aneurysm, and intends to eventually expand her research into other areas of cardiovascular biology where the full complexity of external and internal molecular context must be understood in order to best predict the cause-and-effect relationships between cell signaling and pathophysiology. To achieve this goal, Dr. Parker intends to bridge focused mass spectrometry-based discovery workflows with careful biological validation and the pre-clinical testing of novel therapeutic candidates that will be used to treat specific pathologies. This award will be fundamental in supporting Dr. Parker to build the framework for a research program that will achieve her career goals. Furthermore, by completing the aims of this proposal Dr. Parker will make a significant contribution toward the development of new treatments that will prevent the debilitating consequences of aortic aneurysm.